TMCnet News
Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus
[December 28, 2020]
Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus
First NDA submission for Companyâs lead program, KORSUVA⢠Injection â
NDA submission includes request for Priority Review under Breakthrough Therapy Designation for KORSUVA Injection â
STAMFORD, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for KORSUVA⢠Injecti
Press release content from Business Wire. The AP news staff was not involved in its creation.
Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 21, 2020 GMT
BOSTON (BUSINESS WIRE) Dec 21, 2020
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that its previously announced public offering closed on December 21, 2020. The total number of ordinary shares sold by the Company in the offering was 9,343,750, inclusive of the full exercise of the underwriters’ option to purchase up to an additional 1,218,750 shares, at the public offering price of $8.00 per share, less underwriting discounts and commissions. After giving effect to the option closing, the shares sold by the Company resulted in aggregate gross proceeds to the Company of $74.75 million before deducting underwriting disco
Shattuck Labs Added to Russell 2000® and 3000® Indexes – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Shattuck Labs Added to Russell 2000® and 3000® Indexes
Shattuck Labs, Inc.December 18, 2020 GMT
AUSTIN, TX and DURHAM, NC, Dec. 18, 2020 (GLOBE NEWSWIRE) Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will be added to the Russell 2000® and 3000® Indexes effective December 21, 2020, following Russell’s quarterly additions of select initial public offerings.
“We are incredibly pleased to be included in the Russell 2000® and Russell 3000® Indexes,” said Andrew Neill, Shattuck’s Vice President of Finance and Corporate Strategy. “This milestone reflects the potential that investors see in Shattuck. Importantly, it increases our visibility in the inve
4D pharma Joins Landmark Parkinson s Progression Markers Initiative A landmark study sponsored by The Michael J. Fox Foundation to better understand Parkinson s disease and accelerate the development of new treatments 4D pharma will play an important role as PPMI considers the microbiome as an area of focus Leeds, UK, December l8, 2020 , - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that it has joined the Parkinson s Progression Markers Initiative (PPMI) as an industry partner. PPMI is a landmark study sponsored by The Michael J. Fox Foundation to better understand Parkinson s disease and accelerate the development of new treatments.